Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid Tumors
09 April 2022 - 3:00AM
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell
therapy to treat cancer, presented data from the multinational,
multicenter, screening protocol (NCT02636855) at the American
Association for Cancer Research (AACR) annual meeting in a poster
entitled “Identifying MAGE-A4-Positive Tumors for SPEAR T-Cell
Therapies in HLA-A*02–Eligible Patients”.
“This large clinical dataset continues building the science
around MAGE-A4 expression, and provides a broad, real-world
understanding of patient eligibility for our clinical trials with
SPEAR T-cell therapies targeting MAGE-A4,” said Elliot Norry,
Adaptimmune’s Chief Medical Officer. “This information confirms the
potential of our MAGE-A4 franchise and our continued commitment to
patients and clinicians.”
The screening protocol prospectively evaluated HLA types and
MAGE-A4 expression levels to determine eligibility for the
Company’s clinical trials with SPEAR T-cells targeting MAGE-A4
across a broad range of solid tumors. To be eligible, patients are
required to be HLA-A*02 positive1 and tumor samples need to meet
protocol-defined MAGE-A4 expression levels2 . Data were collected
for screening in the Phase 1 trial of afami-cel (formerly ADP-A2M4;
closed to enrollment) as well as the ongoing Phase 1 SURPASS
trial.
Results from this large dataset are consistent with data
previously shared by the Company and support MAGE-A4 as an
important cancer target within the tumor types currently included
in ongoing clinical trials of afami-cel and ADP-A2M4CD8.
Across sites in the US, Canada, and Spain, a total of 6167
patients had their HLA-A type accurately determined and 2729
(44.3%) were eligible based on protocol-defined criteria. Among
HLA-eligible patients, 1543 had tumor samples evaluable for MAGE-A4
with 313 (20%) meeting the requirements for MAGE-A4 expression.
The rate of eligible MAGE-A4 expression levels was highest in
synovial sarcoma (67%) and ranged from 20% to 35% across the
following solid tumor indications: squamous small cell lung (35%);
bladder (32%), esophagogastric junction (26%), ovarian (24%), head
and neck squamous cell (22%), and esophageal (21%) cancers.
About AdaptimmuneAdaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products for people with cancer. The
Company’s unique SPEAR (Specific Peptide Enhanced Affinity
Receptor) T-cell platform enables the engineering of T-cells to
target and destroy cancer across multiple solid tumors.
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Annual Report on Form
10-K filed with the Securities and Exchange Commission for the year
ended December 31, 2021, our Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K, and other filings with the Securities
and Exchange Commission. The forward-looking statements contained
in this press release speak only as of the date the statements were
made and we do not undertake any obligation to update such
forward-looking statements to reflect subsequent events or
circumstances.
Adaptimmune Contacts:
Media Relations:
Sébastien Desprez — VP, Corporate Affairs and CommunicationsT:
+44 1235 430 583M: +44 7718 453
176Sebastien.Desprez@adaptimmune.com
Investor Relations:
Juli P. Miller, Ph.D. — VP, Investor RelationsT: +1 215 825
9310M: +1 215 460 8920Juli.Miller@adaptimmune.com
__________________1 HLA-A*02:01P, 02:02P, 02:03P, and 02:06P
alleles are eligible; A*02:05P is excluded2 MAGE-A4 expression
level is defined by protein (P) score, which is the percentage of
tumor cells staining at 2+, 3+ by immunohistochemistry (IHC) using
the clinical trial assay. Tumor samples with P scores ≥30% are
considered eligible per protocol. Of note, P score is a
quantification used internally at Adaptimmune. H-score is assessed
as part of the Company’s translational research but is not used for
eligibility.
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Apr 2023 to Apr 2024